BMJ  2007;335:1172-1173 (8 December), doi:10.1136/bmj.39419.369282.DB

News

US gene therapy trial is to restart, despite patient’s death

Janice Hopkins Tanne

1 New York

The first 150 words of the full text of this article appear below.

The US Food and Drug Administration has allowed the resumption of clinical trials of an experimental form of gene therapy for inflammatory arthritis. Trials were suspended in July when a patient died after a second injection into the knee joint of the gene based therapy developed by Targeted Genetics Corporation of Seattle, Washington.

Targeted Genetics said in a press release that the FDA had reviewed data on safety concerning all 127 patients in the trial of the treatment, which used tgAAC94, an investigational gene therapy product developed to treat active inflammatory arthritis, as well as data from the patient who died. The investigation found that the drug did not contribute to her death, the company said.

The Recombinant Advisory Committee of the National Institutes of Health (NIH) met on 3 December to consider the patient who died. Voting on the findings was postponed to the next meeting.

At the meeting . . . [Full text of this article]


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to StumbleUpon StumbleUpon   Add to Technorati Technorati    What's this?

Access jobs at BMJ Careers
Whats new online at Student BMJ